Study Title

Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Preliminary Efficacy of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

Study Details

Description:

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of Lutetium Lu 177 JH020002 Injection in adult patients with advanced prostate cancer.

Sponsor:

Bivision Pharmaceuticals, Inc.

Contacts:

Bivision Pharmaceuticals, Inc.

bivision.public1@bivisionpharma.com

86-21-50886996

Government Study Link:

NCT06139575 - Click here to see study on

ClinicalTrials.gov

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468